|

Zalifrelimab Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: AGEN1884, anti-CTLA4, checkpoint blockade

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 1

Top Sponsors

  • University of Colorado, Denver1
  • ImmunoGenesis1
  • Ann & Robert H Lurie Children's Hospital of Chicago1

Indications

  • Cancer3
  • Metastatic Soft-tissue Sarcoma1
  • Advanced Soft-tissue Sarcoma1
  • Metastatic Head and Neck Squamous Cell Carcinoma1
  • Metastatic Pancreatic Cancer1

Orange, California1 trial

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Children's Health Orange County (CHOC)

Phase 1

Aurora, Colorado1 trial

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

University of Colorado Hospital

Phase 2

Houston, Texas1 trial

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

MD Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.